Turn Therapeutics is pioneering innovative approaches to treat eczema and other skin disorders through its patented drug delivery technology, PermaFusion. This unique system allows for the deep penetration of active ingredients, effectively targeting the root causes of eczema without the need for needles or steroids. The technology is designed to inhibit key immune signals, such as IL-36 and IL-31, which are responsible for initiating the eczema process. By reducing the concentration of active ingredients while maintaining efficacy, PermaFusion minimizes potential side effects, making it a safer alternative for patients.

In addition to its focus on eczema, Turn Therapeutics is expanding its applications to other medical conditions, including onychomycosis (nail fungus). The versatility of their FDA-cleared formula has been validated through extensive clinical data, demonstrating its effectiveness across various skin and wound conditions. With a commitment to safety and efficacy, the company is well-positioned to advance its platform technology into a broader spectrum of drug therapies, aiming to address multiple health needs while minimizing the risk of antibiotic resistance and promoting cooperation with the microbiome.

United States

Turn Therapeutics® is a concept to approval pharmaceutical and medical device organization dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics® was founded with a goal of reducing antibiotic resistance through best in class acute and chronic wound care products. Through research and development, we have continued to uncover additional disease areas that our technology will serve. Our core mission is to leverage our expertise in drug delivery to create disruptive products for high need indications.

Turn Therapeutics

Company Details